Literature DB >> 11684057

Testosterone reduces pentylenetetrazole-induced ictal activity of wildtype mice but not those deficient in type I 5alpha-reductase.

C A Frye1, M E Rhodes, A A Walf, J P Harney.   

Abstract

Testosterone's (T) anti-seizure effects may be mediated in part by actions of its 5alpha-reduced metabolites. To test this hypothesis, T was administered to knockout mice deficient in the 5alpha-reductase type I enzyme and wildtype controls and their ictal activity following pentylenetetrazole (PTZ; 85 mg/kg i.p.) was compared to mice administered vehicle. T to wildtype mice increased latencies to forelimb clonus, tonic clonic seizures, hindlimb extension, and death compared to that seen with vehicle administration. Moreover, incidence of tonic clonic seizures and hindlimb extension were reduced in wildtype mice administered T compared to vehicle-administered mice. T administration to wildtype mice reduced ictal activity compared to T to knockout mice, which were not different than vehicle-administered control mice. T to wildtype mice increased the latencies and decreased the incidence of forelimb clonus compared to T to knockout mice, which were not different from vehicle-administered mice. These data are consistent with T having anti-convulsant effects and that 5alpha-reduced metabolites may mitigate some of T's anti-seizure effects.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11684057     DOI: 10.1016/s0006-8993(01)02967-5

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  11 in total

1.  Type 1 5α-reductase may be required for estrous cycle changes in affective behaviors of female mice.

Authors:  Carolyn J Koonce; Alicia A Walf; Cheryl A Frye
Journal:  Behav Brain Res       Date:  2011-09-21       Impact factor: 3.332

2.  Non-stereo-selective cytosolic human brain tissue 3-ketosteroid reductase is refractory to inhibition by AKR1C inhibitors.

Authors:  Stephan Steckelbroeck; Dieter Lütjohann; David R Bauman; Michael Ludwig; Anke Friedl; Volkmar H J Hans; Trevor M Penning; Dietrich Klingmüller
Journal:  Biochim Biophys Acta       Date:  2010-07-29

Review 3.  Neuroendocrine considerations in the treatment of men and women with epilepsy.

Authors:  Cynthia L Harden; Page B Pennell
Journal:  Lancet Neurol       Date:  2013-01       Impact factor: 44.182

Review 4.  Animal models of absence epilepsies: what do they model and do sex and sex hormones matter?

Authors:  Gilles van Luijtelaar; Filiz Yilmaz Onat; Martin J Gallagher
Journal:  Neurobiol Dis       Date:  2014-08-15       Impact factor: 5.996

5.  Sex Differences in Ethanol's Anxiolytic Effect and Chronic Ethanol Withdrawal Severity in Mice with a Null Mutation of the 5α-Reductase Type 1 Gene.

Authors:  Michelle A Tanchuck-Nipper; Matthew M Ford; Anna Hertzberg; Amy Beadles-Bohling; Debra K Cozzoli; Deborah A Finn
Journal:  Behav Genet       Date:  2014-10-31       Impact factor: 2.805

6.  The testosterone-derived neurosteroid androstanediol is a positive allosteric modulator of GABAA receptors.

Authors:  Doodipala Samba Reddy; Kuihuan Jian
Journal:  J Pharmacol Exp Ther       Date:  2010-06-15       Impact factor: 4.030

7.  Null mutation of 5α-reductase type I gene alters ethanol consumption patterns in a sex-dependent manner.

Authors:  Matthew M Ford; Jeffrey D Nickel; Moriah N Kaufman; Deborah A Finn
Journal:  Behav Genet       Date:  2014-11-23       Impact factor: 2.805

8.  Mass spectrometric assay and physiological-pharmacological activity of androgenic neurosteroids.

Authors:  Doodipala S Reddy
Journal:  Neurochem Int       Date:  2007-06-13       Impact factor: 3.921

Review 9.  Sex Differences in the Epilepsies and Associated Comorbidities: Implications for Use and Development of Pharmacotherapies.

Authors:  Catherine A Christian; Doodipala Samba Reddy; Jamie Maguire; Patrick A Forcelli
Journal:  Pharmacol Rev       Date:  2020-10       Impact factor: 25.468

10.  Role of hormones and neurosteroids in epileptogenesis.

Authors:  Doodipala Samba Reddy
Journal:  Front Cell Neurosci       Date:  2013-07-31       Impact factor: 5.505

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.